Notably, in non-small-cell lung cancer (NSCLC), NOX4 mediates resistance to EGFR-targeted tyrosine kinase inhibitor (TKI) therapy by enhancing IL-8 and PD-L1 expression, thus promoting immune evasion and therapeutic resistance [13]. Here, EGFR is linked to non-small cell lung carcinoma.